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Objective: Homeostasis of the immune system is maintained by apoptotic elimination of potentially pathogenic autore-
active lymphocytes. Emerging evidence shows that Fas-mediated apoptosis is impaired in activated lymphocytes from
patients with autoimmune disease. The aim of this work was to assess apoptosis mediated by the cell death receptor Fas
in peripheral T lymphocytes from patients with abdominal aortic aneurysms (AAA).
Methods: The apoptotic pathway was triggered by anti-Fas monoclonal antibodies in cultured and activated peripheral
T-cell lines from 20 AAA patients with control groups of 15 patients with aortic atherosclerotic occlusive disease (AOD)
and 25 healthy individuals. Cell survival and death (apoptosis) rate were assessed.
Results: Cross-linkage of Fas receptor exerted a strong apoptotic response on T cells from AOD patients and healthy
controls, but a much less pronounced effect on T cells from AAA patients. The evaluation of cell survival rate showed a
significantly higher percentage in AAA group (98.9% 10.3%) than in the AOD subjects (58.9% 15.2%) or the healthy
group (59.4% 12.9%; P< .001). Apoptosis assessment by annexin V and propidium iodide staining and flow cytometry
showed similar results. The defect in AAA group was not due to decreased Fas expression, since Fas was expressed at
normal levels. Moreover, it specifically involved the Fas system because cell death was induced in the normal way by
methylprednisolone. Complementary DNA sequencing identified no causal Fas gene mutation, but two silent single
nucleotide polymorphisms with higher frequency were found in the AAA group.
Conclusions: Fas-induced apoptosis in activated T cells from AAA patients is impaired. This may disturb the normal
down-regulation of the immune response and thus provide a new insight into possible mechanisms and routes in the
pathogenesis of AAA. (J Vasc Surg 2007;45:1039-46.)
Clinical Relevance: Abdominal aortic aneurysm (AAA) represents a common degenerative vascular condition associated
with progressive aortic dilation and life-threatening implications. Despite surgical advances, the recent interest in developing
new therapies for treating small, asymptomatic, non-operation-indicated AAA has led to greater efforts to investigate and
define the cellular and molecular nature of aneurysm degeneration. So far, the clinical aspects of the immune response in AAA
remain limited. This study demonstrated an impaired Fas-induced apoptosis of T lymphocytes in AAA patients, suggesting a
deficiency of the immune response–silencing system. This deficiency may be a novel factor involved in the development of aortic
aneurysm-specific autoimmunity. Thus, our results are important to establish a role for autoimmunity in the etiology of AAA
and are important for the further strategy to develop new therapies for AAA.Abdominal aortic aneurysms (AAA) represent a com-
mon vascular condition associated with progressive aortic
dilation and life-threatening risk of rupture. Recent human
tissue and animal model studies focused on their distinct
aspects of immune and inflammatory responses have led to a
significant change in the pathogenetic concept of AAAs. 1,2
Most aneurysmal disease has thereby proven to be a complex
and dynamic remodeling process rather than a simple degen-
erative condition.
Increasing evidence shows that the immune response
contributes importantly to aneurysmal disease, raising the
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doi:10.1016/j.jvs.2006.12.055probability that autoimmunity may be responsible for the
pathogenesis and development of AAA. In brief, studies
have identified extensive inflammatory infiltrates in the
media and adventitia of AAA, leading to an increased
expression of proinflammatory cytokines and mediating
much of the connective tissue destruction in the aortic
wall.3,4
The main cell population found in these inflammatory
infiltrates is T lymphocytes (CD3), with relative fewer B
cells, macrophages, and plasma cells.1-3 Analysis of lym-
phoid areas in the adventitia from AAA tissues indicates the
existence of T lymphocytes with antigen-presenting cells,
including B cells, macrophages, and others. These areas
may locally serve as sites for both cellular and humoral
immune response.5 Phenotypic characterization of the in-
filtrating lymphocytes reveals that AAA-infiltrating T and B
lymphocytes consist of activated memory cells with specific
B-T costimulation properties.6
The role for autoimmunity has also been supported by
immunogenetic findings with the presence of human lym-
phocyte antigen (HLA)-DR T cells and monocytes in
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alleles and susceptibility to AAAs.9,10 AAA tissues display
local deposition of immunoglobulin, potentially reflecting
humoral immune response; and further, the immunoglob-
ulin G purified from AAA specimens is immunoreactive
with proteins isolated from normal aortas.11-13
Fas (also called CD95 and Apo-1) is a type I transmem-
brane protein belonging to the tumor necrosis factor
(TNF) superfamily, which is expressed on the surface of
activated lymphocytes.14 Once triggered by its cognate
ligand (FasL), Fas initiates a cascade of events within the
cell that culminates in the death of the cell (apoptosis)14
(Fig 1). Fas/FasL-induced apoptosis is crucial for the elim-
inating autoreactive T lymphocytes in the peripheral tissue
to maintain lymphocyte homeostasis.14,15
Recently, defective Fas function leading to impaired Fas-
induced apoptosis has been identified in activated T lympho-
cytes in patients with autoimmune disorders, among them
autoimmune lymphoproliferative syndrome (Canale-Smith
syndrome), asthma, multiple sclerosis, type 1 diabetes melli-
tus, and autoimmune thyroid disease.19-21 In these circum-
stances, the failure of activated lymphocytes to undergo
apoptosis alters the immune response shutting-off system
and promotes autoimmunity. Fas has been shown to be
Fig 1. Apoptosis signaling by FasL. Binding of FasL to Fas in-
duces trimerization of the Fas receptor, which recruits caspase-8 or
10 via an adaptor, Fas-associated death domain protein (FADD).
The oligomerization of caspase 8 and 10 may result in self-
activation of proteolytic activity, and trigger the caspase cascade,
including processing effector caspases 3 and 7. The activated
caspase members can cleave various substrates, resulting in degra-
dation of chromosomal DNA and apoptosis.well expressed throughout AAA tissues, prominently inlymphoid areas.22 No apoptotic T lymphocyte was de-
tected in our previous study, however, as we tried to define
positive apoptotic cell types by using double immunohis-
tochemical staining with specific T-cell marker anti-CD3,23
nor was it reported in another study.22
These observations create the possibility that the Fas
function of T cells in AAA patients may be defective, and T
cells may be resistant to Fas-induced apoptosis. This might
play an important role in autoimmunity of the disease.
Thus, the aim of present work was to evaluate Fas-induced
apoptosis in activated peripheral T cells from AAA patients
and compare it with control groups of aortic atherosclerotic
occlusive disease (AOD) and healthy individuals.
MATERIALS AND METHODS
Human subjects. We studied 20 patients with infra-
renal AAA (17 men, 3 women), who were a median age of
65.5 years (range, 49 to 69 years), undergoing elective
operation of aneurysm repair. The sizes of the aneurysmal
lesions estimated by computed tomography (CT) scan or
magnetic resonance imaging (MRI) were 3.5 to 8.2 cm in
diameter. The patient with the AAA diameter of 3.5 cm had
simultaneously one side of an iliac aneurysm (5.0 cm in
diameter) combined; the other AAAs were all 5.0 cm in
diameter. Patients with Ehlers-Danlos syndrome, Marfan
syndrome, and other known connective tissue disorders
were excluded, and the study patients had no evidence or
medical history of other autoimmune diseases.
To avoid any possible interference from the factor of
atherosclerosis, which always influences elderly patients and
to which recent attention has also been given for the
inflammatory processes and possible autoimmune reactions
especially in the early lesions,24 we set two control groups.
For the normal group, we selected 25 relatively
younger, healthy individuals (17 men, 8 women) with a
median age of 37 years (range, 26 to 52 years). They had a
relatively healthy peripheral vascular system and no evi-
dence or medical history of aneurysm, AOD, or other
vascular disease or of known autoimmune diseases. Thus, T
lymphocytes from AAA patients would be known to be
resistant or sensitive to Fas-induced apoptosis when com-
pared with normal healthy individuals.
Because AAAs are also accompanied by prominent
atherosclerosis, we selected 15 patients (12men, 3 women)
with infrarenal AOD to be in the second control group.
Their median age was 60 years (range, 35 to 66 years), and
they had no evidence or medical history of aneurysmal
disease or known autoimmune diseases, confirmed by CT
scan or MRI. This control group served in part to exclude
the interference of atherosclerosis. All control studies were
performed at same time as the AAA group study.
All subjects gave informed consent. The study was
approved by the Institutional Review Board at Medical
School of University of Heidelberg and the local ethical
committee.
Immunophenotype analysis. Expression of surface
molecules was evaluated by direct immunofluorescence and
flow cytometry using fluorescence-activated cell sorting
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clonal antibodies to CD3 (Per-cp conjugated), and Fas
(CD95) phycoerythrin-conjugated (BD Bioscience, Heidel-
berg, Germany) on fresh and activated peripheral blood lym-
phocytes in which the portion of T lymphocytes and Fas
expression were determined respectively.
T-cell preparation and culture. T-cell preparation
and activation were done as previously described.20,25
Briefly, peripheral blood mononuclear cells (PBMC) were
obtained from heparinized peripheral blood of the subjects.
Isolation was done by density gradient centrifugation with
lymphocyte separation solution (PAALaboratories, Pasching,
Germany), followed by several washing steps. After plastic
adherence for 2 hours at 37°C to deplete monocytes, cell
viability was determined by trypan blue dye exclusion assay,
and cells were incubated at a density of 1 to 2 106/mL in
Roswell Park Memorial Institute-1640 containing 2 mM
glutamine, 10% fetal calf serum, 100 U/mL penicillin, 110
g/mL streptomycin (C.C.Pro., Oberdorla, Germany)
and 2 U/mL recombinant interleukin-2 (Roche, Mann-
heim, Germany). In experiments of induced apoptosis,
T-cell lines were established by activation of PBMC with
phytohemagglutinin (Roche, Mannheim, Germany) first at
days 0 (5 g/mL) and then at day 12 (1 g/mL), and
subsequently in presence of recombinant interleukin-2 (2
U/ml), followed by their cultures.
Analysis of Fas-induced cell death. Fas-induced cell
death in T cells was evaluated as previously described .20,25
Fas function was assessed 6 days after the second activation
of phytohemagglutinin (18-day cultured cells) by incubat-
ing cells in a 96-well plate (1 105 per 0.2 mL/well) with
1 g/mL anti-Fas monoclonal antibodies (CH11, Upstate
Biotechnology, Lake Placid, NY) or control medium in the
presence of recombinant interleukin-2 (1 U/mL) to min-
imize spontaneous cell death. Cell survival was evaluated 24
hours after the incubation by the trypan blue exclusion test,
in which relative cell survival percentage was calculated as
(total live cell count in the assay well/total live cell count in
the control well)  100.
The same conditions were also applied to analyze cell
death induced by 100 mM of methylprednisolone (PDN;
Aventis, Frankfurt, Germany) or 50 mM C2-ceramide (N-
acetyl-D-sphingosine; Sigma, Munich, Germany). The
normal range of T-cell response to Fas-mediated, C2-
ceramide–mediated, or PDN-mediated relative survival
rate at the day of analysis was defined as the mean  two
standard deviations (SD) of data (percentage cell survival)
obtained from normal, healthy individuals.20,25
In addition to the above indirect cell death evaluation by
counting total surviving cells through the trypan blue exclu-
sion test, a direct evaluation using annexin V–fluorescein-5-
isothiocyanate and propidium iodide (BDBioscience,Heidel-
berg, Germany) staining and flow cytometry was applied, in
which cells in earlier apoptosis were stained with annexin V
and cells in late apoptosis were stained with both annexin V
and propidium iodide. The percentage of specific cell death
(early and late apoptosis) was calculated as: 100 [apopto-
tic cells in the assay well (%) – apoptotic cell death in thecontrol well (%)]/[100% – apoptotic cell death in the
control well (%)].
Analysis of Fas gene. For Fas-resistant cases, muta-
tion analysis of the Fas gene was performed by reverse
transcriptase-polymerase chain reaction (RT-PCR) and
complementary DNA (cDNA) sequencing. Total RNAwas
extracted from the cell lines using Qiagen RNeasy Kit
(Hilden, Germany), and 3 g of RNA was used in cDNA
synthesis reactions with RevertAid H Minus First Strand
cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany).
The indicated fragments were amplified by 35 cycles in a
thermocycler (Eppendorf Mastercycler Personal, Hamburg,
Germany). The primers were selected to amplify the Fas open
reading frame (Fas full: sense: 5=-CACTTCGGAGGATTG-
CTCAACA-3=; antisense: 5=-TATGTTGGCTCTTCAGCG-
CTA-3=, 1167bp) or to amplify two segments named Fas I
(sense:5=-AATGCCCAAGTGACTGACATC-3=; antisense:5=-
TCTTCACCCAAACAATTAGTG-3=, 507bp) and Fas II
(sense: 5=-TGCAAAGA GGAAGGATC-3=; antisense: 5=-
TCTAGACCAAGCTTTGGATTTC-3=, 571bp).
The reaction conditions were 35 cycles of 95°C for 30
seconds, 56°C for 45 seconds, and 72°C for 90 seconds (for
three primers), and TaqDNA polymerase (Fermentas) was
used for amplification. The amplified products were electro-
phoretically visualized on 1.5% agarose gel stained by SYBR
Green I nucleic acid gel stain (Cambrex, Rockland, Me),
purified with QIAquick PCR Purification Kit (Qiagen,
Hilden, Germany), and sequenced by MWG Biotech AG
(Martinsried, Germany) facilities. To control potential
PCR error, three different PCR reactions (Fas full, Fas I,
and Fas II) were sequenced individually. When common
mutations were found in more than two PCR results, we
regarded them as definite mutations. Sequence analysis was
performed using the DNAstar Lasergene software package
(DNAstar, Madison, Wis).
Statistical analysis. Statistical analysis was performed
using SPSS 10.0 software (SPSS Inc, Chicago, Ill). The
Mann-WhitneyU test and the Fisher exact test were used as to
evaluate differences in categoric variables. All values were
expressed as mean SD. Statistical significance was accepted
at P .05.
RESULTS
Expression of cell surface molecules. Expression of
cell surface molecules evaluated by direct immunofluores-
cence and FACS analysis showed that the proportion of T
cells (CD3) was 90% at each time of assay. Most T cells
from each case expressed Fas antigen on their surface, with
percentage of 92.4%  7.0% in the AAA group, which was
not significantly different from 90.6%  5.2% in the AOD
group and 88.4%  4.8% in the normal group (P  .05).
Functional analysis of the Fas pathway. Fas-induced
cell death was evaluated indirectly in activated T cells
derived from 20 AAA patients, 15 AOD patients, and 25
normal individuals by the trypan blue exclusion test. We
also assessed the response of T cells to C2-ceramide, whose
pathway overlaps that of Fas,26 and to PDN, whose func-
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system25 (Table I).
During cell cultures, there was no significant difference
among the AAA, AOD, and the normal groups in their cell
proliferative responses. On day 18, before the time of apopto-
sis induction, the T-cell densities in AAA, AOD, and normal
groups were, respectively, 11.5 6.6 100%, 12.2 6.5
100%, and 9.6 5.7 100% of those on day 0 separately
(P  .05).
Results showed that cross-linkage of Fas receptor ex-
erted a strong apoptotic response on activated T cells from
the AOD and normal groups, with a less pronounced effect
on T cells from AAA patients. T cells from patients with
AAA displayed a significantly higher survival rate than those
with AOD and the normal group after treatment with
anti-Fas mAb or C2-ceramide (P  .001). In contrast,
responses to PDN showed no significant difference.
No significant difference was found between patients
with AOD and normal healthy individuals in their response
to Fas or C2-ceramide–induced cell death (Table I). Thus,
compared with normal, healthy individuals, T cells from the
AAA group are Fas-resistant; and compared with the AOD
group, T cells from the AAA group are also Fas-resistant.
Spontaneous cell loss in the control well was10% of the
seeded cells, which was similar in cultures from the AAA and
control groups. The normal ranges of T-cell response to
Fas-mediated, C2-ceramide–mediated, and PDN-mediated
relative survival rate at the day of analysis, defined as themean
two SD of data obtained from 25 normal healthy individ-
uals, were 59.4 25.8 for Fas, 58.5 29.8 for C2-ceramide,
and 57.4  30.0 for PDN. Subjects with a relative survival
percentage of 85.2%, 88.3%, or 87.4% after treatments
were, consequently, considered as Fas-resistant, C2-cermide–
resistant, or PDN-resistant, respectively. The single-patient
data thus showed that 18 of the 20 patients with AAA were
resistant to Fas-induced cell death and 15 were resistant to
C2-ceremide–induced cell death. These frequencies were
significantly higher than those displayed by AOD and nor-
mal, healthy individuals (P  .01; Fig 2). Only two patients
with AAA displayed a Fas response in the normal range; in
contrast, three were resistant to PDN-induced cell death,
Table I. Cell death induced by Fas, C2-ceramide, and me
disease, and abdominal aortic aneurysm groups
Treatment N
Anti-Fas
Resistant*
Relative cell
survival†
C2-
Re
Normal group 25 1 (4) 59.4  12.9
AOD 15 0 (0)‡ 58.9  15.2‡
AAA 20 18 (90)§ 98.9  10.3|| 1
AOD, aortic atherosclerotic occlusive disease; AAA, abdominal aortic aneu
*Value expressed as n (%) of subjects resistant to identical cell-death stimul
†Value expressed as mean  standard deviation of the relative cell surviv
Mann-Whitney U test.
‡Not significantly different from normal group, P  .05.
§Significantly different from two control groups, P  .01.
||Significantly different from two control groups, P  .001.and this frequency was not significantly different from thatdisplayed by AOD subjects (2/15) or normal, healthy
individuals (1/25; P  .05).
Similar results were obtainedwhen Fas-induced apoptosis
as a percentage of specific cell death was evaluated by FACS
and annexin V and propidium iodide staining (Fig 3). We also
tried to detect a possible association of the relative percentages
of cell survival and specific cell death with the size of AAAs in
Fas-resistant patients, but found no definite correlation. No
infection occurred during cell culture, so the possibility of viral
transformations of cell lines can be excluded.
Analysis of the Fas gene. Because decreased function
of Fas may be due to mutations of the Fas gene, we
therefore searched for mutations of the Fas gene in 18
Fas-resistant AAA patients. Sequencing of the Fas gene
locus from AAA patients revealed no causal mutations.
Silent single nucleotide polymorphisms (SNP) 568A¡G in
exon 3 and 988C¡T in exon 7 were detected, as previously
reported in other diseases27,28 (Table II). The frequency of
SNP 988C¡T in AAA patients (6/18) was higher than
that of AOD patients (1/15) and normal, healthy individ-
uals (1/25; P  .05). The genotypes of SNP 988C¡T in
AAA were CC (12/18), CT (5/18), and TT (1/18).
Those in AOD patients were CC (14/15) and CT (1/15),
and in the normal group were CC (24/25) andCT (1/25).
DISCUSSION
The present study evaluated Fas function of peripheral
T lymphocytes in AAA patients after stimulation and cul-
ture as reflecting local T-lymphocyte activation and recruit-
ment in AAA tissues; meanwhile, it identified a distinct
immune property of circulating T lymphocytes in AAA
patients. Our data demonstrate for the first time, to our
knowledge, that activated peripheral T cells from a substan-
tial proportion of AAA patients are hyporesponsive to
Fas-induced apoptosis, displaying a defect in response to
Fas triggering. The ability of Fas to induce apoptosis de-
pends on its connection with a death signal pathway in
which several cysteine proteinases, named caspases, are
activated.12
The death pathway triggered by C2-ceramide is also
defective in a large number of AAA patients. Because
rednisolone in normal, aortic atherosclerotic occlusive
ide
t*
Relative cell
survival†
Methylprednisolone
Resistant*
Relative cell
survival†
58.5  14.9 1 (4) 57.4  15.0
64.7  15.0‡ 2 (13)‡ 64.6  21.4‡
)§ 96.0  10.1|| 3 (15)‡ 63.0  22.2‡
ach group. Statistical analysis was performed with the Fisher exact test.
detected after 24 hours incubation. Statistical analysis was performed bythylp
ceram
sistan
0 (0)
0 (0)‡
5 (75
rysm.
us in e
al (%)C2-ceramide triggers a death pathway that overlaps that of
contr
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tance to both Fas and ceramide triggering. The defect
seems to be specific for the Fas pathway, because most
subjects displayed a normal death response to PDN, whose
cell death pathway does not involve the Fas system.
The process of apoptosis is important both for the dele-
tion of autoreactive lymphocytes and the down-regulation of
appropriately generated immune responses. Thus, the re-
duced susceptibility of peripheral T lymphocytes to apoptosis
suggests that potentially pathogenic, autoreactive cells have
the capacity to survive and may proliferate within AAA tissue
and the circulatory system. This may decrease the efficiency of
the lymphocyte down-regulation system and thus initiate a
series of biochemical and biomechanical activities that directly
relate to the dilation of the abdominal aorta.3 Thus, the
present study corroborates the Fas-induced apoptotic impair-
ment in peripheral T cells to actual AAA tissue and establishes
a possible role for autoimmunity in the etiology of AAA.
Although our previous study demonstrates that the
AAA walls contain more cells (smooth muscle cells and
macrophages) bearing markers of apoptosis, no apoptotic
lymphocytes were found,23 nor have they been reported in
other studies.22 This suggests that under the same condi-
tions, lymphocytes may be resistant to apoptosis while
other cells undergo cell death. He et al,29 in their study of
thoracic aortic aneurysms and type A aortic dissections,
Fig 2. T cell death induced by Fas, C2-ceramide, and m
aneurysm (AAA), aortic atherosclerotic occlusive disease
cell survival percentage.Horizontal lines indicate the uppe
standard deviations from data obtained from 25 normalshow that the T lymphocyte and macrophage infiltrationand apoptotic staining are more pronounced in the media
of dissected aortas, and T lymphocytes bear apoptotic
markers.29 However, aortic dissection is an entity different
from aortic aneurysm in many aspects. A 2005 study by
Duftner et al30 shows that the percentages of CD28– T cells
are significantly expanded in the peripheral blood of AAA
patients who have no history or clinical signs of any other
immune-mediated disease, and the T cells display a reduced
spontaneous apoptosis. This observation supports the idea
of AAA as a T-cell–mediated process and an impaired
apoptosis pathway in T cells from AAA patients.
There are, nonetheless, several possible mechanisms
that would explain the resistance to Fas-induced apoptosis
by T cells from AAA patients. One explanation is due to
inherited genetic alterations similar to those causing auto-
immune lymphoproliferative syndrome, which often dis-
play a dominant negative effect.16 The defect shown in the
present study was different from those displayed by patients
with autoimmune lymphoproliferative syndrome Ia or Ib,
because no Fas gene mutation was found. Fas was normally
expressed on T cells, and FasLwas not involved because our
present method of triggering by Fas mAb is independent of
FasL.
The detected silent SNP 568A¡G and 988C¡T, with
a higher frequency in the AAA group than in the AOD
group and in normal, healthy individuals, do not seem to
lprednisolone (PDN) in patients with abdominal aortic
D), and normal controls. Results are expressed as relative
it of normal range, which is calculated as themean two
ols.ethy
(AO
r limaffect the steady-state expression of Fas by changing the
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expression of Fas itself or may be linked to other genetic
abnormalities playing a role in the pathogenesis of the
disease.27,28 This is a study with very small sample, how-
ever, and the association of these silent polymorphism
coding regions with AAA remains to be defined in a larger
population.
A second putativemechanism for defective Fas function
may be due to an increased release of biologic active inhibitors
of T-cell apoptosis. For example, soluble Fas, a secreted form
of the Fasmolecule that lacks the transmembrane domain, has
been shown to inhibit activation-induced apoptosis in auto-
immune diseases.31
Finally, the defect might be related to the Fas signal
pathway, in which caspase 10 mutation, for instance, has
been detected in some patients.32 A few of over-expressed
inhibitory molecules such as FLIP (FLICE-inhibitory pro-
tein, which in turn is FADD [Fas-associated death domain
protein]-like interleukin-1-converting enzyme]), survi-
nin, inhibitor of apoptosis proteins, and Bcl-2, and others,
in lymphocytes have also been reported to inhibit caspases
in a number of autoimmune diseases.14,33,34
The present study also shows a significant difference
between AAA and AOD patients in the response of their
lymphocytes to Fas-induced apoptosis. The defective T-cell
Fig 3. Fas-induced cell death (apoptosis) detected as percent-
age of relative cell survival by the trypan blue exclusion test
(column group I) and as a percentage of specific cell death
detected by fluorescence activated cell sorting analysis using
annexin V and propidium iodide (PI) staining in which cells in
earlier apoptosis were annexin V–positive and PI-negative,
whereas cells in late apoptosis were both annexin V–positive and
PI-positive (column group II [early and late apoptosis] and III
[early apoptosis only]). Both methods detected defective Fas
function of T cells in patients with abdominal aortic aneurysm
(AAA). Results are expressed as means  standard deviation. A
significant inverse correlation was found between the two meth-
ods (relative cell survival vs early and late apoptosis, r  –0.75,
P  .001).Fas function in AAA patients suggests the unique way of AAAdevelopment, which may be different from AOD and inde-
pendent of atherosclerosis. This question has beendebated for
quite a long time. Further, the significant difference observed
between AAA and AOD in respect to inflammatory infiltra-
tion and immune response within the aortic wall1,35,36 might
be an important factor to influence the direction in which the
arterial disease develops: dilation or obstruction.
Our results also show two cases with AAA that
displayed a Fas response in normal range, which is con-
tradicted by our suggestion that deficiency of the Fas-
induced apoptosis may be involved in AAA development.
However, predisposing to AAA is based on multiple
factors and may involve factors controlling autoantigen
expression, lymphocyte responsiveness, and several as-
pects of immune effector functions. Further, the expres-
sion patterns of the disease may be affected by residual
Fas function and the function of other systems involved
in apoptosis induction, such as TNF and TNF-related
apoptosis inducing ligands, and the granzyme systems,
whose apoptosis pathways partly overlap those of
Fas.37,38
Fas-induced apoptosis in peripheral blood lymphocytes
is not affected by age as identified in previous and recent
studies.39,40 Thus, the use of relatively younger healthy
individuals should not limit the present study. The
younger, healthy individuals have relatively normal periph-
eral vascular systems and have an advantage of being less
influenced by atherosclerosis. AOD is frequently set as a
control when AAA is studied. In fact, AOD with known
intimal atherosclerotic change that is also prominent in
AAA serves as an even better control when age and sex are
matched.
CONCLUSION
The impaired Fas-induced apoptosis of T lymphocytes
in AAA patients identified in this study suggests a deficiency
of the immune response–silencing system. This deficiency
may be a novel factor involved in the development of aortic
aneurysm-specific autoimmunity and thus provide a new
insight into possible mechanisms and routes in the patho-
genesis of AAA.17,18
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